Related Experiment Video
Updated: Sep 9, 2025
07:16
Author Spotlight: Advancements in DNA Nanosensors – Addressing Sensitivity and Selectivity Challenges in Molecular Detection
Published on: February 9, 2024
1.1K
Tetrahedral DNA Framework-Engineered Magnetic Nanozyme for Visual Biomarker Sensing via Alkaline
Mengde Zhao1, Jiahui Zhang1, Lihua Wang2
1School of Materials Science and Engineering, Shanghai University of Engineering Science, Shanghai 201620, China.
Analytical Chemistry
|September 4, 2025
Summary
This study presents a novel naked-eye, colorimetric biosensor for prostate-specific antigen (PSA) detection. The platform offers high sensitivity and selectivity for early prostate cancer screening at the point-of-care.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Analytical Chemistry
Background:
- Point-of-care (POC) detection of prostate-specific antigen (PSA) is crucial for early prostate cancer (PCa) screening and management.
- Existing POC platforms often lack sensitivity, are prone to interference, and require complex sample preparation.
Purpose of the Study:
- To develop a sensitive, selective, and user-friendly POC colorimetric sensing platform for PSA detection.
- To overcome the limitations of current POC methods for prostate cancer biomarker analysis.
Main Methods:
- A novel sensing platform integrating magnetic nanozymes (Fe3O4@ZIF-67@Pt) with a tetrahedral DNA framework (TDF).
- Utilized ALP-triggered hydrolysis and competitive aptamer recognition for signal amplification.
- Employed magnetic separation and DNA-conjugated interface engineering for enhanced performance.
Main Results:
- Achieved naked-eye and colorimetric detection of PSA in the range of 0.1-1000 ng/mL.
- Demonstrated a low detection limit of 36 pg/mL with excellent selectivity.
- Validated high accuracy and reliability in human serum samples, distinguishing PCa patients from healthy individuals.
Conclusions:
- The developed platform offers a promising solution for reliable POC PSA detection.
- This technology has significant potential for advancing early prostate cancer diagnosis and monitoring.
- The integrated nanozyme and DNA framework approach enables superior biosensing capabilities.
